Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab
Authors:
Open Access
- 28 March 2017
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 8 (5) , 175-180
Abstract
Nivolumab is a humanized immunoglobulin gamma-4 kappa anti-programmed cell death 1 monoclonal antibody that is currently approved in the treatment of several solid tumors and recently gained accelerated approval in classical Hodgkin lymphoma (cHL) that has relapsed or progressed following autologous hematopoietic stem-cell transplantation and post-transplantation brentuximab vedotin. The purpose of this article is to review the immunophysiologic basis, clinical efficacy, and toxicity of nivolumab in the treatment of cHL. In addition, we will review ongoing clinical trials and potential future directions of checkpoint inhibition in the treatment of cHL.Keywords
This publication has 31 references indexed in Scilit:
- A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphomaBlood, 2011
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood, 2010
- Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology ConsortiumLeukemia & Lymphoma, 2010
- A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphomaAmerican Journal of Hematology, 2010
- The biology of Hodgkin's lymphomaNature Reviews Cancer, 2008
- Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphomaAnnals of Oncology, 2008
- Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantationBone Marrow Transplantation, 2008
- Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s LymphomaTransplantation and Cellular Therapy, 2006
- Salvage Radiotherapy in Patients With Relapsed and Refractory Hodgkin’s Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma Study GroupJournal of Clinical Oncology, 2005
- Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphomaBone Marrow Transplantation, 2003